• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The role of biological response modifiers in metastatic renal cell carcinoma.

作者信息

Muss H B

机构信息

Cancer Center of Wake Forest University, Department of Medicine, Bowman-Gray School of Medicine, Winston-Salem, NC 27103.

出版信息

Semin Oncol. 1988 Oct;15(5 Suppl 5):30-4.

PMID:2461595
Abstract
摘要

相似文献

1
The role of biological response modifiers in metastatic renal cell carcinoma.生物反应调节剂在转移性肾细胞癌中的作用。
Semin Oncol. 1988 Oct;15(5 Suppl 5):30-4.
2
Interferons and interleukins in metastatic renal cell carcinoma.转移性肾细胞癌中的干扰素和白细胞介素
Urology. 1993 Jan;41(1 Suppl):67-72. doi: 10.1016/0090-4295(93)90199-k.
3
Immunotherapy for metastatic renal cell carcinoma.转移性肾细胞癌的免疫疗法。
Urol Clin North Am. 1993 May;20(2):283-95.
4
Systemic therapy of metastatic renal cell carcinoma.转移性肾细胞癌的全身治疗
Semin Nephrol. 1987 Jun;7(2):152-62.
5
Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.射频消融联合白细胞介素-2 诱导小鼠肾细胞癌抗肿瘤免疫反应。
J Urol. 2012 Aug;188(2):607-14. doi: 10.1016/j.juro.2012.03.116. Epub 2012 Jun 15.
6
The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer.干扰素、白细胞介素-2和肿瘤坏死因子目前在肾细胞癌治疗中的应用。
Urol Int. 1991;47(4):219-30. doi: 10.1159/000282226.
7
[The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].[干扰素、白细胞介素-2和肿瘤坏死因子在肾细胞癌治疗中的价值]
Urologe A. 1991 Mar;30(2):77-80.
8
[Immunotherapy of metastatic renal cell cancer].[转移性肾细胞癌的免疫治疗]
Urologe A. 1993 Sep;32(5):360-73.
9
[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].干扰素和白细胞介素与放疗联合的抗肿瘤作用。第一部分：免疫学基础
Strahlenther Onkol. 2004 Apr;180(4):187-93. doi: 10.1007/s00066-004-9119-x.
10
Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.白细胞介素-2与α干扰素联合生物疗法用于转移性肾细胞癌的门诊治疗
Semin Oncol. 1993 Dec;20(6 Suppl 9):11-5.

引用本文的文献

1
CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.CD70（肿瘤坏死因子超家族成员7）在肾细胞癌中高表达，且在抗体结合后会迅速内化。
Br J Cancer. 2006 Aug 7;95(3):298-306. doi: 10.1038/sj.bjc.6603222.
2
Significance of angiogenesis and microvascular invasion in renal cell carcinoma.血管生成和微血管侵犯在肾细胞癌中的意义
Pathol Oncol Res. 2002;8(2):129-32. doi: 10.1007/BF03033722.
3
Altretamine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group trial.
六甲蜜胺用于治疗转移性肾细胞癌。一项印第安纳肿瘤学组试验。
Invest New Drugs. 2001;19(3):229-31. doi: 10.1023/a:1010620601431.
4
Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.肾细胞癌患者对一组细胞生长抑制剂药物及干扰素α-2b的体外药敏测定
Int Urol Nephrol. 1997;29(4):421-6. doi: 10.1007/BF02551107.
5
Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.依托泊苷增强重组人肿瘤坏死因子对人肾细胞癌的体内细胞毒性。临床前模型评估。
Urol Res. 1990;18(4):245-50. doi: 10.1007/BF00294766.
6
Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study.
Invest New Drugs. 1990 Aug;8(3):307-9. doi: 10.1007/BF00171843.
7
Ifosfamide, vindesine and recombinant alpha-interferon combination chemotherapy for metastatic renal cell carcinoma.异环磷酰胺、长春地辛与重组α干扰素联合化疗治疗转移性肾细胞癌。
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S221-3. doi: 10.1007/BF01613231.
8
Tumors of the kidney, ureter, and bladder.肾、输尿管和膀胱肿瘤。
West J Med. 1992 May;156(5):523-34.
9
Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial.
Invest New Drugs. 1992 Apr;10(1):51-4. doi: 10.1007/BF01275483.